Fluoxetine, widely recognized under the brand name Prozac, is a medication approved by the Food and Drug Administration (FDA) for its effectiveness in treating a range of mental health conditions. This medication has proven beneficial in managing major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, bulimia nervosa, binge eating disorder, premenstrual dysphoric disorder (PMDD), and depressive episodes associated with bipolar disorder. In cases of treatment-resistant depression, fluoxetine can also be used in combination with olanzapine. This article delves into the various FDA-approved and off-label uses of fluoxetine, its mechanism of action, administration, potential side effects, contraindications, and monitoring aspects, providing a comprehensive understanding of this widely used drug.
FDA-Approved Uses of Prozac (Fluoxetine)
Fluoxetine has secured FDA approval for treating several conditions across different age groups. These approved indications highlight its role as a versatile medication in psychiatric treatment.
Major Depressive Disorder (MDD): Fluoxetine is approved for treating MDD in adults and children aged 8 years and older. It is a cornerstone in managing the persistent sadness, loss of interest, and other symptoms characteristic of depression, helping to stabilize mood and improve overall well-being.
Obsessive-Compulsive Disorder (OCD): For individuals aged 7 years and older, fluoxetine is an effective treatment for OCD. It aids in reducing the intrusive thoughts and compulsive behaviors that define this disorder, enabling patients to gain better control over their daily lives.
Panic Disorder: Fluoxetine is also indicated for the treatment of panic disorder, with or without agoraphobia, in adults. By mitigating the frequency and intensity of panic attacks, fluoxetine helps individuals manage the overwhelming anxiety and fear associated with this condition.
Bulimia Nervosa: In the realm of eating disorders, fluoxetine is FDA-approved for treating bulimia nervosa in adults. It is often used alongside cognitive-behavioral therapy (CBT) to address the binge-purge cycles and distorted body image issues prevalent in bulimia. The American Psychiatric Association guidelines specifically recommend fluoxetine as a first-line pharmacotherapy, in conjunction with CBT, for bulimia nervosa patients.
Bipolar I Disorder – Depressive Episodes: Fluoxetine is approved as an adjunctive therapy with olanzapine for treating depressive episodes linked to Bipolar I disorder. This combination is particularly useful in managing the depressive phases of bipolar disorder, helping to balance mood fluctuations.
Treatment-Resistant Depression: When depression proves resistant to standard treatments, fluoxetine, combined with olanzapine, is an FDA-approved option. This combination approach addresses more complex depressive conditions that do not respond to typical antidepressant monotherapy.
Off-Label Uses of Fluoxetine
Beyond its FDA-approved indications, fluoxetine is also used off-label to treat a range of other conditions. Off-label use means that the drug is used in a manner not specifically approved by the FDA but is supported by clinical evidence and professional guidelines.
Binge Eating Disorder: While not formally FDA-approved for binge eating disorder, fluoxetine is used to help manage this condition. It can aid in reducing the frequency of binge eating episodes and improve control over eating habits.
Social Anxiety Disorder: Fluoxetine has shown efficacy in treating social anxiety disorder, helping individuals overcome excessive fear and avoidance of social situations.
Premenstrual Dysphoric Disorder (PMDD): PMDD, a severe form of premenstrual syndrome, can be effectively managed with fluoxetine. It helps alleviate the mood swings, irritability, and anxiety associated with PMDD.
Borderline Personality Disorder (BPD): Although not a primary treatment, fluoxetine is sometimes used to manage certain symptoms of borderline personality disorder, such as emotional instability and impulsivity.
Raynaud Phenomenon: Fluoxetine has been explored for the treatment of Raynaud phenomenon, a condition causing reduced blood flow to the fingers and toes in response to cold or stress.
Selective Mutism: In children and adolescents with selective mutism, a condition characterized by a consistent failure to speak in specific social situations despite speaking in others, fluoxetine may be used as part of a comprehensive treatment plan.
Post-Traumatic Stress Disorder (PTSD): The American Psychological Association endorses fluoxetine for the treatment of PTSD. It can help manage symptoms like re-experiencing traumatic events, avoidance behaviors, and hyperarousal.
How Prozac Works: Mechanism of Action
Fluoxetine’s therapeutic effects stem from its mechanism of action as a selective serotonin reuptake inhibitor (SSRI). Serotonin is a neurotransmitter that plays a crucial role in mood regulation, emotions, sleep, appetite, and other functions.
Inhibiting Serotonin Reuptake: Fluoxetine primarily works by blocking the reuptake of serotonin in the presynaptic neurons of the brain. After serotonin is released into the synapse (the gap between nerve cells), it transmits signals. Normally, serotonin is then reabsorbed back into the presynaptic neuron, a process called reuptake. Fluoxetine inhibits the serotonin transporter protein, which is responsible for this reuptake. By blocking this transporter, fluoxetine increases the amount of active serotonin available in the synapse.
Impact on Serotonin Levels: This increased availability of serotonin in the synaptic cleft enhances serotonergic neurotransmission. It is believed that by boosting serotonin levels, fluoxetine helps to improve mood, reduce anxiety, and alleviate symptoms of depression and other psychiatric conditions.
Other Receptor Activity: While primarily an SSRI, fluoxetine also has mild activity at the 5-HT2A and 5-HT2C receptors, which are subtypes of serotonin receptors. However, its main therapeutic action is attributed to the selective inhibition of serotonin reuptake.
Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination
Understanding how fluoxetine is processed in the body is crucial for effective and safe usage. Its pharmacokinetic properties influence dosing, potential drug interactions, and duration of effects.
Absorption: Fluoxetine is well absorbed in the body after oral administration, with a bioavailability of 70% to 90%. Peak plasma concentrations are typically reached within 6 to 8 hours after ingestion. Food intake does not significantly affect its bioavailability but might delay absorption by 1 to 2 hours, which is usually not clinically relevant. Thus, fluoxetine can be taken with or without food.
Distribution: Fluoxetine exhibits high plasma protein binding, approximately 94.5%, primarily to albumin and alpha-1 glycoprotein. It readily crosses the blood-brain barrier, achieving a brain-to-plasma ratio of 2.6:1 in humans, indicating effective penetration into the central nervous system. The volume of distribution is substantial, ranging from 20 to 42 L/kg, and some studies suggest it has the highest volume of distribution among SSRIs, ranging from 14 to 100 L/kg.
Metabolism: Fluoxetine is metabolized in the liver, primarily by the cytochrome P450 enzyme CYP2D6. The main active metabolite is norfluoxetine, which is also formed through CYP2D6 activity. This metabolic pathway is significant because fluoxetine can interact with other drugs metabolized by CYP2D6, potentially leading to drug-drug interactions. Furthermore, norfluoxetine can inhibit CYP3A4, another important cytochrome P450 enzyme. Approximately 7% of individuals are poor metabolizers of fluoxetine due to reduced CYP2D6 activity, which can affect drug response and side effects.
Elimination: Fluoxetine and norfluoxetine have long elimination half-lives. Fluoxetine’s half-life is 2 to 4 days, while norfluoxetine’s is even longer, at 7 to 9 days. These long half-lives mean that fluoxetine and its active metabolite remain in the body for several weeks after the last dose. This is a critical consideration when discontinuing fluoxetine or when starting other medications that might interact with it post-discontinuation. Only a small percentage, about 2.5% of the administered dose, is excreted unchanged in the urine, indicating extensive metabolism.
Prozac Dosage and Administration
Proper administration and dosage are essential for optimizing the therapeutic effects of fluoxetine and minimizing potential side effects.
Available Dosage Forms and Strengths: Fluoxetine is available in various oral formulations:
- Oral Solution: 20 mg/5 mL
- Tablets: 10 mg, 20 mg, 60 mg
- Capsules: 10 mg, 20 mg, 40 mg
- Delayed-Release Capsules: 90 mg
It is also available in a fixed-dose combination with olanzapine, containing 6 mg of olanzapine and 25 mg of fluoxetine.
General Administration: Fluoxetine is typically administered once daily, either in the morning or evening. Starting doses are usually 20 mg daily. Dosage adjustments are made based on individual patient needs and response, generally ranging from 20 mg to 40 mg daily for most conditions. For patients sensitive to side effects, lower starting doses of 10 mg may be used.
Weekly Dosage: For maintenance treatment, a delayed-release capsule formulation of 90 mg, taken once weekly, is available. This weekly formulation has demonstrated similar efficacy to the 20 mg daily formulation, offering convenience for some patients.
Adult Dosing for Specific Conditions:
- Major Depressive Disorder: Starting dose is 20 mg daily, with a maximum recommended dose of 80 mg daily.
- Obsessive-Compulsive Disorder: Starting dose is 20 mg daily, with a typical maintenance dose ranging from 20 to 60 mg daily.
- Bulimia Nervosa: A dose of 60 mg daily is recommended, particularly if psychotherapy alone is insufficient after 6 weeks.
- Panic Disorder: Starting dose is lower, at 10 mg daily, increasing to 20 mg daily after one week, with a maximum recommended dose of 60 mg daily.
Special Patient Populations:
- Hepatic Impairment: Patients with liver cirrhosis require lower and less frequent doses due to decreased clearance of fluoxetine and norfluoxetine. Caution is advised in patients with any condition affecting drug metabolism.
- Renal Impairment: No standard dose adjustment is needed for renal impairment. Weekly fluoxetine may be a viable option for hemodialysis patients.
- Pregnancy: Fluoxetine is Pregnancy Category C. It should be used cautiously during pregnancy, especially in the third trimester, due to potential complications in newborns. Tapering fluoxetine in the third trimester may be considered.
- Breastfeeding: Fluoxetine is excreted in breast milk, and breastfeeding is generally not recommended while taking fluoxetine. If fluoxetine is necessary, monitoring the infant for adverse effects is crucial.
- Pediatric Patients: For children and adolescents with MDD and OCD, the starting dose is 10 mg daily. Fluoxetine is considered a first-line medication for depressive disorders in this age group.
- Older Patients: The starting dose for older adults is typically 10 mg daily, which can be increased to 20 mg as tolerated.
Prozac Side Effects
Like all medications, fluoxetine can cause side effects. Understanding these potential effects is important for patient management and adherence to treatment.
Common Side Effects: The most frequently reported side effects in adults include:
- Insomnia
- Nausea
- Diarrhea
- Anorexia
- Dry mouth
- Headache
- Drowsiness
- Anxiety
- Nervousness
- Yawning
- Bruising
- Hyperhidrosis (excessive sweating)
- Sexual dysfunction (decreased libido, anorgasmia, ejaculation latency)
- Weight changes (gain or loss)
- Muscle weakness
- Tremors
- Pharyngitis
Less Common but Notable Side Effects:
- Seizures (rare)
- Bleeding (rare)
- Mania induction
- Activation of suicidal ideation and behavior (especially in teenagers and young adults)
- Panic attacks
- Agitation
Managing Side Effects: Most side effects are immediate and tend to diminish over time. Educating patients about this is crucial. If insomnia occurs, taking fluoxetine in the morning may help. Dose reduction can be considered if side effects are distressing. For persistent or severe side effects, switching to a different antidepressant might be necessary after a few weeks.
Serious Side Effects:
- Serotonin Syndrome: A potentially life-threatening condition that can occur when fluoxetine is combined with other serotonergic agents or in overdose. Symptoms include changes in mental status, autonomic instability, and neuromuscular abnormalities.
- Reversible Cerebral Vasoconstriction Syndrome (RCVS): Severe headache associated with vasoconstriction of cerebral arteries has been reported.
- Rabbit Syndrome: Rare movement disorder characterized by rhythmic, fine movements of the mouth, similar to a rabbit chewing.
- Hyponatremia: Low sodium levels, possibly due to syndrome of inappropriate antidiuretic hormone (SIADH).
- QT Prolongation: Fluoxetine can prolong the QT interval, increasing the risk of cardiac arrhythmias.
- Angle-Closure Glaucoma: Fluoxetine may cause angle closure glaucoma.
Drug Interactions with Prozac
Fluoxetine can interact with numerous other medications, primarily due to its metabolism via CYP2D6 and its inhibitory effects on CYP2D6 and CYP3A4.
CYP2D6 Interactions: Fluoxetine can increase the serum concentrations of drugs metabolized by CYP2D6, such as:
- Tricyclic Antidepressants (TCAs): Concurrent use can elevate TCA levels, requiring dosage adjustments.
- Antipsychotics: Fluoxetine can increase levels of haloperidol and clozapine. Co-administration with aripiprazole can increase QT interval prolongation risk.
- Antiarrhythmics: Class 1A and Class III antiarrhythmics combined with fluoxetine can increase QT interval.
Other Significant Interactions:
- Benzodiazepines: Fluoxetine can increase plasma concentrations of alprazolam and diazepam, potentially leading to increased sedation.
- Warfarin: Fluoxetine increases the risk of bleeding when used with warfarin. PT/INR monitoring is necessary.
- NSAIDs/Aspirin: Increased risk of upper gastrointestinal bleeding with concurrent use.
- Anticonvulsants: Fluoxetine can increase plasma concentrations of phenytoin and carbamazepine, requiring therapeutic drug monitoring.
- Serotonergic Agents: Combining fluoxetine with other serotonergic drugs (triptans, tramadol, lithium, St. John’s Wort, etc.) increases the risk of serotonin syndrome.
- MAOIs: Contraindicated with MAOIs due to high risk of serotonin syndrome.
Contraindications and Warnings for Prozac
Certain conditions and concurrent medications contraindicate the use of fluoxetine.
Contraindications:
- Hypersensitivity to fluoxetine or any formulation component.
- Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 2 weeks of discontinuing an MAOI.
- Use with pimozide or thioridazine due to QT prolongation risk.
- Starting fluoxetine in a patient receiving linezolid.
Boxed Warning:
- Increased risk of suicidal ideation and behavior in children, adolescents, and young adults (18-24 years old). Close monitoring is essential, especially at the start of treatment and during dose changes.
Warnings and Precautions:
- Pregnancy: Not recommended during pregnancy unless benefits outweigh risks. Potential risks include septal heart defects and pulmonary hypertension in newborns.
- Electroconvulsive Therapy (ECT): Seizures have been reported with ECT and fluoxetine. Caution is advised in patients undergoing ECT.
- Allergic Reactions and Rash: Discontinue fluoxetine if rash or allergic reactions occur, including Stevens-Johnson syndrome.
- Mania/Hypomania Activation: Screen for bipolar disorder before starting fluoxetine, as it can trigger manic episodes.
- Anxiety and Insomnia: May exacerbate anxiety and insomnia in some patients.
- Angle-Closure Glaucoma: Monitor intraocular pressure in patients with glaucoma history.
- Hyponatremia: Risk of low sodium levels.
- QT Prolongation: Use cautiously in patients with risk factors for QT prolongation.
- Cognitive Impairment: May impair cognitive and motor skills. Caution advised when performing tasks requiring alertness.
- Sexual Dysfunction: Common side effect.
Monitoring Patients on Prozac
Regular monitoring is crucial to ensure the safety and effectiveness of fluoxetine treatment.
Clinical Monitoring:
- Assess for depression and suicidal risk, especially at treatment initiation and dose changes.
- Monitor for anxiety, panic attacks, social functioning, and mania/mood lability.
- Watch for signs and symptoms of serotonin syndrome.
- Use rating scales like PHQ-9 and HAM-D/HDRS to track treatment progress.
Laboratory Monitoring:
- Routine lab tests are not generally needed for healthy individuals.
- In older adults or specific populations, consider blood glucose and liver function tests.
- ECG may be warranted in patients with QT prolongation risk factors.
- Monitor height and weight in pediatric patients.
Washout Period: The American Society of Regional Anesthesia (ASRA) recommends a 5-week washout period before interventional procedures due to bleeding risk.
Prozac Overdose and Toxicity
Fluoxetine overdose alone is rarely lethal. However, it can be more serious when combined with alcohol or other serotonergic agents.
Symptoms of Overdose:
- Serotonin syndrome
- Ataxia
- Respiratory depression (when combined with alcohol)
Management of Overdose:
- Supportive care is the mainstay of treatment.
- Airway protection and respiratory support.
- Serial ECGs to monitor for cardiotoxicity.
- Benzodiazepines for sedation.
- Activated charcoal for GI decontamination.
- Cyproheptadine for serotonin syndrome.
Enhancing Healthcare Team Outcomes
Effective fluoxetine therapy requires a collaborative interprofessional team approach.
Team Roles:
- Physicians and Advanced Practitioners: Prescribe and manage fluoxetine therapy, considering benefits and risks, especially in pregnant women.
- Nursing Staff: Monitor patients for suicidal ideation, counsel on dosing and administration, and ensure regular follow-ups.
- Pharmacists: Verify dosing, check for drug interactions, and advise prescribers and patients.
Interprofessional Communication: Open communication and collaboration among clinicians, specialists, nurses, and pharmacists are essential for optimal patient outcomes and minimizing adverse effects. Regular monitoring, patient education, and coordinated care ensure fluoxetine is used safely and effectively across various psychiatric conditions.
References
1.Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst Rev. 2019 Apr 12;4(4):CD012680. [PMC free article: PMC6459769] [PubMed: 30977111]
2.Dhenain T, Côté F, Coman T. Serotonin and orthodontic tooth movement. Biochimie. 2019 Jun;161:73-79. [PubMed: 30953672]
3.Burch R. Antidepressants for Preventive Treatment of Migraine. Curr Treat Options Neurol. 2019 Mar 21;21(4):18. [PubMed: 30895388]
4.Crone C, Fochtmann LJ, Attia E, Boland R, Escobar J, Fornari V, Golden N, Guarda A, Jackson-Triche M, Manzo L, Mascolo M, Pierce K, Riddle M, Seritan A, Uniacke B, Zucker N, Yager J, Craig TJ, Hong SH, Medicus J. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders. Am J Psychiatry. 2023 Feb 01;180(2):167-171. [PubMed: 36722117]
5.Li X, Li J, Li X, Wang J, Dai H, Wang J. Effectiveness and safety of fluoxetine for premature ejaculation: Protocol for a systematic review. Medicine (Baltimore). 2019 Feb;98(7):e14481. [PMC free article: PMC6407935] [PubMed: 30762772]
6.Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-777. [PubMed: 30712879]
7.Martin A, Naunton M, Kosari S, Peterson G, Thomas J, Christenson JK. Treatment Guidelines for PTSD: A Systematic Review. J Clin Med. 2021 Sep 15;10(18) [PMC free article: PMC8471692] [PubMed: 34575284]
8.Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000 Jan;85(1):11-28. [PubMed: 10674711]
9.Robertson OD, Coronado NG, Sethi R, Berk M, Dodd S. Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early Interv Psychiatry. 2019 Oct;13(5):1032-1049. [PubMed: 30690898]
10.Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre RS. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 08;92:109-117. [PubMed: 30611836]
11.Delavenne X, Magnin M, Basset T, Piot M, Mallouk N, Ressnikoff D, Garcin A, Laporte S, Garnier P, Mismetti P. Investigation of drug-drug interactions between clopidogrel and fluoxetine. Fundam Clin Pharmacol. 2013 Dec;27(6):683-9. [PubMed: 23413998]
12.Deodhar M, Rihani SBA, Darakjian L, Turgeon J, Michaud V. Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition. Pharmaceutics. 2021 Jan 23;13(2) [PMC free article: PMC7912198] [PubMed: 33498694]
13.Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom. 2015;84(2):72-81. [PubMed: 25721705]
14.Andrade C. Psychotropic Drugs With Long Half-Lives: Implications for Drug Discontinuation, Occasional Missed Doses, Dosing Interval, and Pregnancy Planning. J Clin Psychiatry. 2022 Aug 01;83(4) [PubMed: 35921503]
15.Wagstaff AJ, Goa KL. Once-weekly fluoxetine. Drugs. 2001;61(15):2221-8; discussion 2229-30. [PubMed: 11772132]
16.Kauffman KM, Dolata J, Figueroa M, Gunzler D, Huml A, Pencak J, Sajatovic M, Sehgal AR. Directly Observed Weekly Fluoxetine for Major Depressive Disorder Among Hemodialysis Patients: A Single-Arm Feasibility Trial. Kidney Med. 2022 Mar;4(3):100413. [PMC free article: PMC8978139] [PubMed: 35386606]
17.Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HE, Skaarup L, Videbech P., Danish Psychiatric Society. Danish Society of Obstetrics and Gynecology. Danish Paediatric Society. Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1-28. [PubMed: 26344706]
18.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Aug 15, 2023. Fluoxetine. [PubMed: 30000245]
19.Walter HJ, Abright AR, Bukstein OG, Diamond J, Keable H, Ripperger-Suhler J, Rockhill C. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. J Am Acad Child Adolesc Psychiatry. 2023 May;62(5):479-502. [PubMed: 36273673]
20.Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020 Jun;19(2):214-232. [PMC free article: PMC7215080] [PubMed: 32394557]
21.Gutsmiedl K, Krause M, Bighelli I, Schneider-Thoma J, Leucht S. How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis. BMC Psychiatry. 2020 Mar 04;20(1):102. [PMC free article: PMC7057600] [PubMed: 32131786]
22.Mullen S. Major depressive disorder in children and adolescents. Ment Health Clin. 2018 Nov;8(6):275-283. [PMC free article: PMC6213890] [PubMed: 30397569]
23.Bahar MA, Kamp J, Borgsteede SD, Hak E, Wilffert B. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715. [PMC free article: PMC6255988] [PubMed: 30248178]
24.Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of Antidepressants on Sleep. Curr Psychiatry Rep. 2017 Aug 09;19(9):63. [PMC free article: PMC5548844] [PubMed: 28791566]
25.Manning T, Bartow C, Dunlap M, Kiehl R, Kneale H, Walker A. Reversible Cerebral Vasoconstriction Syndrome Associated With Fluoxetine. J Acad Consult Liaison Psychiatry. 2021 Nov-Dec;62(6):634-644. [PubMed: 34371244]
26.Laban T, Larroche C, Comparon C, Dhôte R, Degos B. Fluoxetine-induced chorea. Rev Neurol (Paris). 2021 Oct;177(8):1010-1011. [PubMed: 34148736]
27.Naguy A, Moodliar-Rensburg S, Elsori DH, Alamiri B. Fluoxetine-Induced “Rabbit Syndrome” in a Child With Juvenile Obsessive-Compulsive Disorder. 2022 May-Jun 01Am J Ther. 29(3):e363-e364. [PubMed: 32384313]
28.Edinoff AN, Fort JM, Woo JJ, Causey CD, Burroughs CR, Cornett EM, Kaye AM, Kaye AD. Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations. Neurol Int. 2021 Sep 01;13(3):445-463. [PMC free article: PMC8482107] [PubMed: 34564289]
29.2021 ACMT Annual Scientific Meeting Abstracts-Virtual. J Med Toxicol. 2021 Mar 31;17(2):93-153. [PMC free article: PMC8011778] [PubMed: 33791944]
30.Wei A, Peng J, Gu Z, Li J. QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature. Medicine (Baltimore). 2017 Dec;96(49):e9071. [PMC free article: PMC5728935] [PubMed: 29245320]
31.Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy. 1997 Jan-Feb;17(1):170-2. [PubMed: 9017779]
32.Spina E, Barbieri MA, Cicala G, Bruno A, de Leon J. Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert Opin Drug Metab Toxicol. 2020 Jan;16(1):31-44. [PubMed: 31795773]
33.de Abajo FJ, Montero D, Rodríguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):304-10. [PubMed: 16611206]
34.Zaccara G, Franco V. Pharmacokinetic Interactions Between Antiseizure and Psychiatric Medications. Curr Neuropharmacol. 2023;21(8):1666-1690. [PMC free article: PMC10514545] [PubMed: 35611779]
35.Park SH, Wackernah RC, Stimmel GL. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants? J Pharm Pract. 2014 Feb;27(1):71-8. [PubMed: 24153222]
36.Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission. Case Rep Med. 2016;2016:7128909. [PMC free article: PMC4940515] [PubMed: 27433163]
37.Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016 May;149(3):139-52. [PMC free article: PMC4860751] [PubMed: 27212965]
38.Selph SS, McDonagh MS. Depression in Children and Adolescents: Evaluation and Treatment. Am Fam Physician. 2019 Nov 15;100(10):609-617. [PubMed: 31730312]
39.Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, Cornett EM, Kaye AM. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021 Aug 05;13(3):387-401. [PMC free article: PMC8395812] [PubMed: 34449705]
40.Riggin L, Frankel Z, Moretti M, Pupco A, Koren G. The fetal safety of fluoxetine: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2013 Apr;35(4):362-369. [PubMed: 23660045]
41.Anderson KN, Lind JN, Simeone RM, Bobo WV, Mitchell AA, Riehle-Colarusso T, Polen KN, Reefhuis J. Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects. JAMA Psychiatry. 2020 Dec 01;77(12):1246-1255. [PMC free article: PMC7407327] [PubMed: 32777011]
42.Chi SH, Jeong HG, Lee S, Oh SY, Kim SH. Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy. Psychiatry Investig. 2017 Sep;14(5):647-655. [PMC free article: PMC5639133] [PubMed: 29042890]
43.Andrade C. Fluoxetine for Stroke: A Mixed Bag of Outcomes. J Clin Psychiatry. 2021 Jun 08;82(3) [PubMed: 34106530]
44.Agrawal R, Almoghrabi A, Attar BM, Gandhi S. Fluoxetine-induced Stevens-Johnson syndrome and liver injury. J Clin Pharm Ther. 2019 Feb;44(1):115-118. [PubMed: 30296343]
45.Akaltun İ, Ayaydin H. Fluoxetine-related mania in an adolescent girl diagnosed with selective mutism: A case report. Asia Pac Psychiatry. 2020 Mar;12(1):e12367. [PubMed: 31222962]
46.Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol. 2008 Dec;6(4):293-310. [PMC free article: PMC2701282] [PubMed: 19587851]
47.Gandhi S, Shariff SZ, Al-Jaishi A, Reiss JP, Mamdani MM, Hackam DG, Li L, McArthur E, Weir MA, Garg AX. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults. Am J Kidney Dis. 2017 Jan;69(1):87-96. [PubMed: 27773479]
48.Seshadri M, Thalitaya MD, Simon T, Odelola C, Enow H. Antidepressants and Hyponatremia in a patient with Colectomy – a Case Report. Psychiatr Danub. 2017 Sep;29(Suppl 3):610-614. [PubMed: 28953839]
49.Zhang L, Liu X, Li T, Xu B, Fu B. Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study. Neuropsychiatr Dis Treat. 2021;17:3819-3825. [PMC free article: PMC8721155] [PubMed: 35002241]
50.Cooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A. Interventions to treat premature ejaculation: a systematic review short report. Health Technol Assess. 2015 Mar;19(21):1-180, v-vi. [PMC free article: PMC4781071] [PubMed: 25768099]
51.Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. Ment Health Clin. 2016 Jul;6(4):191-196. [PMC free article: PMC6007725] [PubMed: 29955469]
52.Lee-Kelland R, Zehra S, Mappa P. Fluoxetine overdose in a teenager resulting in serotonin syndrome, seizure and delayed onset rhabdomyolysis. BMJ Case Rep. 2018 Oct 08;2018 [PMC free article: PMC6194370] [PubMed: 30301727]
53.Sharp R. The Hamilton Rating Scale for Depression. Occup Med (Lond). 2015 Jun;65(4):340. [PubMed: 25972613]
54.Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, Falloon K, Hatcher S. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010 Jul-Aug;8(4):348-53. [PMC free article: PMC2906530] [PubMed: 20644190]
55.Beard C, Hsu KJ, Rifkin LS, Busch AB, Björgvinsson T. Validation of the PHQ-9 in a psychiatric sample. J Affect Disord. 2016 Mar 15;193:267-73. [PubMed: 26774513]
56.Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2018 Apr;43(3):225-262. [PubMed: 29278603]
57.Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, Scharman EJ, Wax PM, Manoguerra AS, Christianson G, Caravati EM, Troutman WG. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007 May;45(4):315-32. [PubMed: 17486478]
58.Patel DD, Galarneau D. Serotonin Syndrome With Fluoxetine: Two Case Reports. Ochsner J. 2016 Winter;16(4):554-557. [PMC free article: PMC5158166] [PubMed: 27999518]
59.Bruggeman C, O’Day CS. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 4, 2023. Selective Serotonin Reuptake Inhibitor Toxicity. [PubMed: 30521236]
60.Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59 Suppl 15:42-8. [PubMed: 9786310]
